Investing

Royalty Pharma : RPRX

RPRX

Stock Data

$39.59

$0.63 (1.62%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Royalty Pharma plc is a key player in the biopharmaceutical industry, specializing in the acquisition of biopharmaceutical royalties and funding innovation. With a focus on collaboration, the company works alongside academic institutions, research hospitals, and companies of various sizes to support the development of new therapies. Its diverse portfolio includes royalties on over 35 commercial products and 14 products in development, covering areas like rare diseases, cancer, and diabetes. Founded in 1996, Royalty Pharma is headquartered in New York, New York, marking its influence in the healthcare sector.

All Royalty Pharma Articles

11 Articles

Rich Duprey | Aug 27, 2024

Goldman Sachs Predicts a Double-Digit Rally for These 2 Growth Stocks

The tech stock selloff in July surprised the market but not those investors who were paying attention. As far back…

Trey Thoelcke | Aug 22, 2024

Prediction: This Health Care Stock Will Be the Best Performer the Rest of 2024

With a market rotation underway, where should investors seeking opportunities in health care be looking? Analysts have high expectations for…

Chris Lange | Jun 14, 2022

Waiting for the Fed to Change: Analysts Upgrade or Downgrade Best Buy, Oracle, Teva Pharma and More

Tuesday's additional top analyst upgrades and downgrades were on Adobe, AstraZeneca, Best Buy, Chemours, Oracle, Royalty Pharma, Teva Pharmaceutical and…

Lee Jackson | Apr 28, 2022

Thursday’s Top Analyst Upgrades and Downgrades: Alphabet, ADM, Capital One, Chipotle, Corning, Microsoft, PepsiCo, Spotify, Texas Instruments, Visa and More

Thursday's top analyst upgrades and downgrades included Alphabet, Allstate, Antero Midstream, Archer Daniels Midland, Capital One Financial, Chipotle Mexican Grill,…

Chris Lange | Apr 14, 2022

Elon Musk’s 4D Chess Move; Analyst Upgrades and Downgrades on Royalty Pharma, Twitter, UPS and More

Thursday’s additional top analyst upgrades and downgrades included Royalty Pharma, Twitter, UPS and more.

Chris Lange | Nov 8, 2020

Beyond Meat, Cisco, Disney, Lyft, McDonald’s and More Major Earnings Coming This Week

24/7 Wall St. has put together a preview of a few of the most anticipated quarterly reports due this week,…

Chris Lange | Sep 10, 2020

5 Very Undervalued Large Cap Biotech Stocks That Could Explode in 2021

Practically any biotech company attempting almost anything COVID-19 related has seen massive gains. However, there is likely more to come…

Lee Jackson | Sep 2, 2020

5 Recent IPOs Still Have Massive Upside Potential

Shares of these recently public companies still offer aggressive investors outstanding entry levels, but most have not seen their lockup…

Chris Lange | Aug 12, 2020

How Is Royalty Pharma Poised After Earnings?

Royalty Pharma reported quarterly results on Wednesday morning that were boosted by Imbruvica and the addition of new royalties.

Chris Lange | Aug 9, 2020

Applied Materials, Barrick, Cisco, DraftKings and More Major Earnings Coming This Week

24/7 Wall St. has put together a preview of Cisco Systems, Nio, Occidental Petroleum and some of the other most…

Chris Lange | Aug 5, 2020

5 Large Biotech and Pharma Stocks Are Dirt Cheap, and Not Because of COVID-19

24/7 has compiled a few biopharmaceutical names that have lagged the markets and recently have reported earnings. In a sense,…